-+ 0.00%
-+ 0.00%
-+ 0.00%

Perspective Therapeutics wins EU orphan drug status for [212Pb]VMT-α-NET in GEP-NETs

PUBT·07/28/2026 10:35:46
Listen to the news
Perspective Therapeutics wins EU orphan drug status for [212Pb]VMT-α-NET in GEP-NETs
  • European Commission granted orphan medicinal product designation for Perspective Therapeutics’ [212Pb]VMT-α-NET in gastroenteropancreatic neuroendocrine tumors.
  • Decision followed a positive opinion from the EMA’s Committee for Orphan Medicinal Products.
  • Status may offer EU development incentives, including fee reductions, protocol support, and up to 10 years of market exclusivity if approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.